(NewsNation) — AbbVie, an Illinois-based pharmaceutical company, entered into a contract to develop an obesity medication with Gubra, a Danish drugmaker. Under the agreement, which was detailed ...

The outlay, plus up to $1.87 billion in milestones, has landed the drugmaker rights to a long-acting amylin analog that is in phase 1 development at Gubra. As a major player in the medical ...

The pharma company announcing a license agreement with a company called Gubra for an obesity drug. Gubra is a Danish research company, will receive $350 million in upfront payments, up to $1.88 ...

AbbVie is entering the obesity treatment market with a $2.3bn licensing agreement to acquire global rights to GUB014295, a long-acting amylin analogue developed by Danish biotech Gubra.

AbbVie has joined the ranks of pharma groups trying to develop weight-loss drugs, licensing a long-acting amylin analogue from Denmark's Gubra in a deal valued at more than $2.2 billion.

HØRSHOLM, DK / ACCESS Newswire / March 10, 2025 / Gubra (CPH:GUBRA)Notice to convene ANNUAL GENERAL MEETING 2025GUBRA A/SCVR NO. 30 51 40 41To the shareholders of Gubra A/S (CVR no. 30 51 40 41 ...

AbbVie is jumping into the burgeoning obesity field, striking a license agreement with Gubra that is potentially worth more than $2 billion to the Danish drug-discovery and contract-research ...

The deal includes a $350 million upfront payment to the company, Gubra, for the rights to its drug, called for now GUB014295. AbbVie will pay up to some $1.9 billion if certain development and ...

Historical Prices for Gubra A-S Bearer and-or registered Shs Gubra A-S Bearer and-or registered Shs Analyst Opinions Gubra A-S Bearer and-or registered Shs Estimates* in DKK Income Statements in Mio.

NORTH CHICAGO, Ill. and HØRSHOLM, Denmark, March 3, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Gubra A/S (CPSE:GUBRA), a company specializing in preclinical contract research services and ...

Partnership marks AbbVie's entrance into the obesity field Agreement will enable the incorporation of GUB014295, an amylin peptide discovered and developed by Gubra, into AbbVie's global ...